Northland analyst Michael Latimore raised the firm’s price target on UpHealth to $11 from $3 and keeps an Outperform rating on the shares. After a "tumultuous 2022," the company has trimmed costs and is deconsolidating its Indian operations, noted the firm, whose FY23 revenue estimate is $132M, or up 9%, and FY24 revenue estimate is $139.4M. The firm is updating its model for Q3 and Q4 results and the reverse stock split, yielding its $11 price target.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on UPH:
- UpHealth Announces Fourth Quarter 2022 Financial Results
- UpHealth sees 2023 revenues $127M-$135M
- UpHealth reports Q4 EPS ($1.82) vs. ($23.64) last year
- UpHealth Announces Timing of Fourth Quarter and Full Year 2022 Earnings Release and Conference Call
- UpHealth announces sale of IGI to Belmar Pharma Solutions for $56M